RT Journal Article
T1 The bitter side of epigenetics: variability and resistance to chemotherapy.
A1 Hajji, Nabil
A1 García-Domínguez, Daniel J
A1 Hontecillas-Prieto, Lourdes
A1 O'Neill, Kevin
A1 de Álava, Enrique
A1 Syed, Nelofer
K1 cancer epigenetics
K1 epigenetic regulations
K1 epigenetic therapies
AB One of the major obstacles to the development of effective new cancer treatments and the main factor for the increasing number of clinical trial failures appears to be the paucity of accurate, reproducible and robust drug resistance testing methods. Most research assessing the resistance of cancers to chemotherapy has concentrated on genetic-based molecular mechanisms, while the role of epigenetics in drug resistance has been generally overlooked. This is rather surprising given that an increasing body of evidence pointing to the fact that epigenetic mechanism alterations appear to play a pivotal role in cancer initiation, progression and development of chemoresistance. This resulted in a series of clinical trials involving epi-drug as single treatment or combined with cancer conventional drugs. In this review, we provided the main mechanisms by which the epigenetic regulators control the resistance to cancer drugs.
YR 2018
FD 2018-06-22
LK https://hdl.handle.net/10668/26722
UL https://hdl.handle.net/10668/26722
LA en
DS RISalud
RD Apr 6, 2025